Home › Compare › TTIRF vs ABBV
TTIRF yields 500000.00% · ABBV yields 3.06%● Live data
📍 TTIRF pulled ahead of the other in Year 1
Combined, TTIRF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TTIRF + ABBV for your $10,000?
Tertiary Minerals plc, together with its subsidiaries, engages in the identification, acquisition, exploration, and development of mineral deposits. The company engages in the development of a multi-commodity project portfolio, including precious metals, base metals, and industrial minerals. It owns interests in the Storuman fluorspar project located in north central Sweden; the Lassedalen fluorspar project located in the south-west of Oslo, Norway; the Pyramid gold project located in the northwest of Reno, Nevada; the Paymaster polymetallic project that includes claims covering an area of 390 acres located in southwest of Tonopah, Nevada; and the Kaaresselkä and Kiekerömaa gold projects located in Finland. The company also holds interests in the Rosendal tantalum project located in south-west Finland; the Lucky copper prospect consisting of 13 claims located in north-east Nevada; and the Mt Tobin prospect comprising claims located to the south of Winnemucca in north central Nevada. Tertiary Minerals plc was incorporated in 1999 and is headquartered in Macclesfield, the United Kingdom.
Full TTIRF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.